Literature DB >> 8145530

A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2.

M B Parr1, L Kepple, M R McDermott, M D Drew, J J Bozzola, E L Parr.   

Abstract

BACKGROUND: The role of mucosal immunity in defense of the female genital tract against pathogens such as herpes simplex virus-2 (HSV-2) is poorly understood. Here we explored the use of a new mouse model to determine whether local immune events in the vagina of immune animals may protect them against genital herpes. EXPERIMENTAL
DESIGN: The effect of the estrous cycle, pregnancy, and sex hormones on vaginal infection of adult mice by HSV-2 was determined by immunolabeling of virus proteins. The immune response to infection was studied by immunolabeling of T lymphocytes, B lymphocytes, and plasma cells in the vagina of infected mice.
RESULTS: Inoculation of attenuated virus (TK-HSV-2) or wild-type virus (TK+HSV-2) into the vagina on day 6 of pregnancy or after treatment with Depo-Provera (DP) caused infection of the vaginal epithelium. In contrast, these viruses did not cause infection after vaginal inoculation at estrus, metestrus, or after treatment with Depo-Estradiol. Infected mice showed immunolabeling of virus in the vaginal epithelium from 24 hrs to 5 days after virus inoculation. The immune response to infection included upregulation of class II MHC antigen in vaginal epithelium, CD8+ T cells in epithelium and stroma, and plasma cells and lymphoid nodules in the stroma. Mice that were infected with TK-HSV-2 did not exhibit infection of vaginal epithelium when challenged 6 weeks later with TK+HSV-2.
CONCLUSIONS: Progesterone-dominated adult mice become infected after intravaginal inoculation with HSV-2, but estradiol-dominated mice are refractory. Vaginal infection with attenuated HSV-2 produces immunity that protects mice against later infection by wild-type virus. This immunity either prevents infection of vaginal epithelium or severely inhibits viral replication in the epithelium. The observations suggest that the E/DP-treated adult mouse should be a useful model for studies of mucosal immunity to vaginal infection by HSV-2.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8145530

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  102 in total

1.  Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity.

Authors:  A M Harandi; B Svennerholm; J Holmgren; K Eriksson
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Thermoreversible gel formulations containing sodium lauryl sulfate or n-Lauroylsarcosine as potential topical microbicides against sexually transmitted diseases.

Authors:  S Roy; P Gourde; J Piret; A Désormeaux; J Lamontagne; C Haineault; R F Omar; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Vaginal formulations of carrageenan protect mice from herpes simplex virus infection.

Authors:  V R Zacharopoulos; D M Phillips
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

4.  Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2.

Authors:  E L Parr; M B Parr
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

5.  Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2.

Authors:  E L Parr; M B Parr
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

6.  Innate control of adaptive immunity via remodeling of lymph node feed arteriole.

Authors:  Kelly A Soderberg; Geoffrey W Payne; Ayuko Sato; Ruslan Medzhitov; Steven S Segal; Akiko Iwasaki
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-31       Impact factor: 11.205

Review 7.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

8.  A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus.

Authors:  Natalie L M Ramsey; Maria Visciano; Richard Hunte; Lip Nam Loh; Clare Burn Aschner; William R Jacobs; Betsy C Herold
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

9.  Immunity to vaginal HSV-2 infection in immunoglobulin A knockout mice.

Authors:  M B Parr; G R Harriman; E L Parr
Journal:  Immunology       Date:  1998-10       Impact factor: 7.397

Review 10.  Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection.

Authors:  Zdenek Hel; Elizabeth Stringer; Jiri Mestecky
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.